Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
COX-2 is a key protein in cancer progression which is involved in proliferation, invasion, and metastasis of tumor cells.
|
27314294 |
2016 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Induction of COX‑2 and membrane‑associated PGE synthase 1 (mPGES‑1), which are overexpressed in numerous cancer types, cooperatively enhance PGE2 expression, which contributes to carcinogenesis and cancer progression.
|
26352871 |
2015 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Macrophages are one of the predominant tumor-infiltrating immune cells supporting key processes in tumor progression by producing protumoral factors such as cyclooxygenase-2 (COX-2).
|
25545478 |
2015 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Integration of metabolomics and molecular and pathological approaches reveals the interplay between cancer and stroma via COX-2, and IDO promotes tumor progression and predicts poor patient survival.
|
25060643 |
2014 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The function of COX-2 in tumor progression has been recently elucidated.
|
24535229 |
2014 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cholangiocarcinogenesis and tumor progression are regulated by a novel interplay between COX-2/PGE2 and miR-21 signaling, which converges at 15-PGDH.
|
24699315 |
2014 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cyclooxygenase-2 (Cox-2) is presumed to contribute to cancer progression through its multifaceted function, and recently its inverse relationship with E-cadherin was suggested.
|
24887090 |
2014 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The induction of cyclooxygenase 2 (Cox-2) by integrin α3β1 in breast cancer cells can promote tumor progression.
|
24434582 |
2014 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Most importantly, we show for the first time that BMM-supplied CTSK may be involved in CCL2- and COX-2-driven pathways that contribute to tumor progression in bone.
|
22614014 |
2013 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor-1 (EGFR), and cyclooxygenase-2 (COX-2) stimulate key processes involved in tumor progression and are important targets for cancer drugs.
|
23801169 |
2013 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Analysis of the contribution of COX-2-dependent PGs to the development of hepatocarcinogenesis, evaluated in this model, suggested a minor role of COX-2-dependent prostaglandins to liver oncogenesis as indicated by liver histopathology, morphometric analysis and specific markers of tumor progression.
|
23579063 |
2013 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Cyclooxygenase-2 (COX-2) is frequently overexpressed in human malignancies and plays a crucial role in tumorigenesis and cancer progression.
|
22922684 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Telomere length in CRCs also had differences with COX-2 status (P=0.004), but did not differ with P53 status (P=0.101), tumor progression (P=0.244), gender (P=0.542), and metastasis (0.488).
|
22524803 |
2012 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
COX-2 is expressed highly in pancreatic cancer and implicated in tumor progression.
|
22829202 |
2012 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, the tertiary RNA-protein complex was predominantly found in the cytoplasm of colon cancer cells; thus, it might be related to COX-2 protein level and cancer progression.
|
22544606 |
2012 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Tumor samples from 118 CRC patients were screened in a retrospective analysis by qRT-PCR for expression of the four tumor progression-associated genes osteopontin (Opn), transforming growth factor β (Tgf-β), matrix metalloproteinase-2 (Mmp-2) and cyclooxigenase-2 (Cox-2).
|
22614156 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cyclooxygenase-2 (COX-2) plays a crucial role in prognosis of malignancy and has been associated with carcinogenesis, particularly neoangiogenesis and tumor progression.
|
22213328 |
2012 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The association of COX-2 expression with tumor progression and prognosis was analyzed.
|
22993369 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The ability of N2IC to enhance tumor progression in SC-M1 cells was suppressed by knockdown of COX-2 or treatment with NS-398, a COX-2 inhibitor.
|
21976141 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
p38 MAPK, ERK, and COX-2 activation are novel mediators for the galectin-1-promoted tumor progression and chemoresistance in lung cancer.
|
22696230 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
IL-1β-dependent induction of COX-2 in breast cancer cells provides a mechanism whereby macrophages contribute to tumor progression and potential therapeutic targets in breast cancer.
|
21310944 |
2011 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Moreover, findings extrapolated from experimental studies in cultured tumor cells and animal tumor models indicate that cyclooxygenase-2 critically influences all stages of tumor development from tumor initiation to tumor progression.
|
21187081 |
2011 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
COX-2 is implicated in carcinogenesis and tumour progression in many cancers, including breast cancer.
|
20536410 |
2010 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Available clinical data establish the protective effect of COX-2 inhibition on human cancer progression.
|
20353998 |
2010 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, these findings indicated that 17beta-HSD12 was not necessarily related to intratumoral E2 biosynthesis, at least in human breast carcinoma, but was rather correlated with production of VLCFAs such as arachidonic acid, which may subsequently be metabolized to prostaglandins by COX2 and result in tumor progression of the patients.
|
19190350 |
2009 |